Current Partnering’s pick of the latest and largest financing announcements…
OncoMed seeks $115 million IPO
May 15, 2012 : financings
OncoMed offers $115M IPO bet on cancer stem cell work more »
Fresenius in public offering for $1.31 billion
May 14, 2012 : financings
Fresenius successfully completes capital increase more »
PROLOR Biotech announced the pricing of its previously announced underwritten public offering of 6.5 million shares of its common stock at a price to the public of $5.00 per share more »
LIfe sciences VC money drops in Q1, 2012
May 10, 2012 : dealtalk, financings
Venture capitalists invested $5.8 billion in 758 deals in the first quarter of 2012, according to the MoneyTree Report more »
Celladon achieves $53 million private placement
May 9, 2012 : financings
Celladon announced the receipt of additional capital proceeds from a second close of its recent venture financing to advance the Company’s lead investigational product candidate MYDICAR for the treatment of advanced heart failure more »
Aviir in $30 million private placement
May 9, 2012 : financings
Agreement with multiple investors to raise up to $30 million in the company’s latest financing round more »
Pacira in debt refinancing deal for $27.5 million
May 4, 2012 : financings
Pacira Pharmaceuticals announced that it has secured a $27.5 million debt financing facility through Oxford Finance more »
Oxford Nanopore Technologies private placement for $50.78 million for single molecule detection technology
May 4, 2012 : financings
Oxford Nanopore says that it raised £31.4 million (about $50.78 million) in new funding via a private placement of ordinary shares in the company more »
Royalty Pharma acquires interest in Fumapharm earnout for $761 million
May 4, 2012 : financings, royalty financing
Royalty Pharma acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash more »
Argos Therapeutics raised $25 million in series D
April 25, 2012 : financings
Argos Therapeutics has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012 more »
